Results 51 to 60 of about 282,663 (297)
Leukemia, 2020 Rambaldi, A., Iurlo, A., Vannucchi, A. M., Noble, R., von Bubnoff, N., Guarini, A., Martino, B., Pezzutto, A., Carli, G., De Muro, M., Luciani, S., McMullin, M. F., Cambier, N., Marolleau, J-P., Mesa, R. A., Tibes, R., Pancrazzi, A., Gesullo, F., Bettica,
A. Rambaldi +20 more
semanticscholar +1 more source
Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]
, 2016 Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core +2 more sources
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]
, 2019 Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V. +8 more
core +1 more source
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 PV must be distinguished from secondary erythrocytosis, and from spurious polycythemia. The diagnosis of PV can reasonably be made in the presence of a raised red cell mass (above 25% above predicted, or hematocrit 0.60 in males or above 0.56 in females), in the absence of causes of secondary erythrocytosis (normal arterial oxygen saturation and no ...
CUNEO, Antonio, CAVAZZINI, Francesco
openaire +3 more sources
Journal of Inflammation Research, 2023 Jing Yuan, Xuan Liu, Zhenzhen Wang, Liyuan Li, Fuxu Wang Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People’s Republic of ChinaCorrespondence: Fuxu Wang, Department of Hematology, The Second ...
Yuan J, Liu X, Wang Z, Li L, Wang F
doaj
Journal of Medical Case Reports, 2018 Background Polycythemia vera is a myeloproliferative disease that sometimes evolves to myelofibrosis, causing splenomegaly and neutropenia. In this case report, we describe a patient with polycythemia vera and unexplained neutropenia who later turned out
Andreas Hanssønn Habberstad +6 more
doaj +1 more source
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]
, 2018 We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo +41 more
core +5 more sources
Thrombotic and hemorrhagic complications in idiopathic erythrocytosis [PDF]
, 2017 We report clinical features of a large cohort of patients with IE compared to a cohort of patients with PV, focusing on the thrombotic and hemorrhagic ...
Bertozzi, Irene +5 more
core +1 more source
The utility of testing erythropoietin level in polycythemia diagnosis
Hematology, 2023 Objectives: Polycythemia vera (PV) is classically thought to be associated with low erythropoietin (EPO) levels. Here, we present a review of the utility of using EPO levels in diagnosing polycythemia.Methods: We conducted a systematic literature review ...
Abdellatif Ismail +7 more
doaj +1 more source
Haematologica, 2012 Background Although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear.
Emil Kuriakose +7 more
doaj +1 more source